Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified

Cited by (261)

Items 101–200 of 261

1. Harmony Within: Unravelling the Microbiome–Immune System Symbiosis for Health
   Anuupama Suchiita, Navya Gupta, Kajal Nandi, Subash Chandra Sonkar, Lal Chandra · 2025 · Advanced Gut & Microbiome Research
2. Microbiota changes with fermented kimchi contributed to either the amelioration or rejuvenation of Helicobacter pylori-associated chronic atrophic gastritis
   Jong Min Park, Won Hee Lee, Hochan Seo, Ji Young Oh, Dong Yoon Lee, Seong-Jin Kim, Ki Baik Hahm · 2021 · Journal of Clinical Biochemistry and Nutrition
3. Human gut microbiome: A primer for the clinician
   Saurabh Kedia, Vineet Ahuja · 2023 · JGH Open
4. What do we know about the variability in survival of patients with amyotrophic lateral sclerosis?
   Pamela McCombe, Fleur C. Garton, Matthew Katz, Naomi R. Wray, Robert D. Henderson · 2020 · Expert Review of Neurotherapeutics
5. Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?
   Axel Dalhoff · 2020 · Infection
6. Biological Roles of Toll-Like Receptors and Gut Microbiota In Colorectal Cancer
   Yinhang Wu, Wei Wu, Zhuang Jing, Qing Zhou, Zhou Yani, Shuwen Han · 2022 · Future Microbiology
7. Investigation of Enterogermina’s Protective and Restorative Mechanisms on the Gut Microbiota with PPI, Using SHIME Technology
   Cindy Duysburgh, Lynn Verstrepen, Mattia Van den Broeck, Zefferino Righetto, Marcos III Perez · 2023 · Nutrients
8. Impact of Environmental and Pharmacologic Changes on the Upper Gastrointestinal Microbiome
   Joshua L. Bilello, Ikenna C Okereke · 2021 · Biomedicines
9. Evaluating the Efficacy of Secondary Metabolites in Antibiotic-Induced Dysbiosis: A Narrative Review of Preclinical Studies
   Corina Andrei, Anca Zanfirescu, Victor-Pierre Ormeneanu, Simona Negreș · 2025 · Antibiotics
10. Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection
    Josh Claypool, Gustav Lindved, Pernille Neve Myers, Tonya Ward, Henrik Bjørn Nielsen, Ken Blount · 2025 · Gut Microbes
11. The Duration of Proton Pump Inhibitor Therapy and the Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis
    Хурматуллина Алсу Расимовна, Д. Н. Андреев, Yu. A. Kucheryavyy, Filipp S. Sokolov, Petr A. Beliy, Andrey Vladimirovich Zaborovsky, Igor Veniaminovich Maev · 2025 · Journal of Clinical Medicine
12. Could modulating the esophageal microbiome be the answer for eosinophilic esophagitis treatment?
    Sonia Facchin, Erica Bonazzi, Antonietta Tomasulo, Luisa Bertin, Greta Lorenzon, Daria Maniero, Fabiana Zingone, Romilda Cardin, Brigida Barberio, Matteo Ghisa et al. · 2025 · Expert Review of Gastroenterology & Hepatology
13. Host–Microbiome Interaction in the Intensive Care Unit
    Maria Adriana Neag, Andrei Otto Mitre, Irina Georgiana Pomana, Maria Amalia Velescu, Claudia Florentina Militaru, Georgiana Anca Nagy, Carmen Stanca Melincovici · 2025 · Diseases
14. Association and Mechanisms of Proton Pump Inhibitors Use with Type-2 Diabetes Mellitus Incidence in Adults: A Systemic Review and Meta-Analysis
    Santenna Chenchula, Phulen Sharma, Mohan Krishna Ghanta, Krishna Chaitanya Amerneni, Padmavathi Rajakarunakaran, Pavani Saggurthi, Madhu Bhargavi Chandra, Rupesh Gupta, Madhavrao Chavan · 2024 · Current Diabetes Reviews
15. The Microbiome Factor in Drug Discovery and Development
    Andrea Nuzzo, James R. Brown · 2019 · Chemical Research in Toxicology
16. Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study
    Chia‐Jung Kuo, Cheng-Yu Lin, Chun-Wei Chen, Chiu-Yi Hsu, Sen‐Yung Hsieh, Cheng‐Tang Chiu, Wey‐Ran Lin · 2021 · Journal of Personalized Medicine
17. Inappropriate Use of Proton Pump Inhibitors Increases Cardiovascular Events in Patients with Coronary Heart Disease
    Wen Hu, Yunhao Luo, Xiujuan Yang · 2022 · International Journal of General Medicine
18. Exposure to proton pump inhibitors is associated with the development of pediatric autoimmune diseases
    Laura Räisänen, Heli T. Viljakainen, Kaija‐Leena Kolho · 2023 · Frontiers in Pediatrics
19. Factors Affecting the Gut Microbiome in Pediatric Intestinal Failure
    Saurabh Talathi, Linda T. Wilkinson, Katie Meloni, Michelle C. Shroyer, Li Zhang, Zhenying Ding, Peter G. Eipers, William Van Der Pol, Colin A Martin, Reed A. Dimmitt et al. · 2023 · Journal of Pediatric Gastroenterology and Nutrition
20. Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models
    Oshin Miranda, Peihao Fan, Xiguang Qi, Haohan Wang, M. Daniel Brannock, Thomas R. Kosten, Neal D. Ryan, Levent Kirisci, Lirong Wang · 2024 · Drug and Alcohol Dependence
21. Use of proton pump inhibitors is associated with a higher risk of pneumonia in cirrhotic patients: a systematic review and meta-analysis
    Wasit Wongtrakul · 2020 · Annals of Gastroenterology
22. Effect of Helicobacter pylori–induced gastric cancer on gastrointestinal microbiota: a narrative review
    Mohsen Heidary, Sousan Akrami, Tohid Madanipour, Nafiseh Hosseinzadeh Shakib, Marzie Mahdizade Ari, Masoumeh Beig, Saeed Khoshnood, Roya Ghanavati, Monireh Bazdar · 2025 · Frontiers in Oncology
23. Can Bioactive Food Substances Contribute to Cystic Fibrosis-Related Cardiovascular Disease Prevention?
    Laura Mihaela Trandafir, Otilia Elena Frăsinariu, Elena Țarcă, Lăcrămioara Ionela Butnariu, Maria Magdalena Leon Constantin, Mihaela Moscalu, Oana Raluca Temneanu, Alina Sinziana Melinte Popescu, Marian George Melinte Popescu, Iuliana Magdalena Stârcea et al. · 2023 · Nutrients
24. Drug Response Diversity: A Hidden Bacterium?
    Nadji Hannachi, Laurence Camoin‐Jau · 2021 · Journal of Personalized Medicine
25. Gastric microbiota and its role in gastric carcinogenesis
    Xiaowen Jiang, Lei Peng, Li Zhang, Zhexuan Li, Tong Zhou, Jingying Zhang, Wenqing Li, Wei‐Cheng You, Yang Zhang, Kai‐Feng Pan · 2023 · Malignancy Spectrum
26. Acid-suppressive medications in the first year of life and risk of childhood asthma: a population-based birth cohort study
    Claudio Barbiellini Amidei, Rosanna Irene Comoretto, Loris Zanier, Daniele Donà, Anna Cantarutti, Cristina Canova · 2020 · European Respiratory Journal
27. Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study
    Wei‐Ting Wang, Cheng‐Yuan Li, Yun-Ting Chang, Ya‐Mei Bai, Shih‐Jen Tsai, Tzeng‐Ji Chen, Shih‐Hwa Chiou, Mu‐Hong Chen · 2023 · Allergy and Asthma Proceedings
28. The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review
    Jixin Chen, Shuqi Chen, Hui Luo, Shunqin Long, Xiaobing Yang, Wenfeng He, Wanyin Wu, Sumei Wang · 2023 · International Immunopharmacology
29. Analysis of Risk Factors for Febrile Neutropenia in Patients with Small-Cell Lung Cancer Receiving Carboplatin Plus Etoposide Therapy
    Masaya Takahashi, Katsuyuki Takahashi, Hiroyasu Kaneda, Tomoya Kawaguchi, Toru Otori, Yasutaka Nakamura · 2023 · Oncology
30. Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors
    Masaya Takahashi, Hitomi Nakatsukasa, Masahito Shibano, Yusuke Ishigami, Takako Oka, Yoko Tani, Tomoya Kawaguchi, Yasutaka Nakamura, Hiroyasu Kaneda · 2025 · International Journal of Clinical Oncology
31. The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer
    Paulina J. Haight, Quinn Kistenfeger, Courtney J. Riedinger, Wafa K. Khadraoui, Floor Jenniskens Backes, Kristin Leigh Bixel, Larry J. Copeland, David E. Cohn, Casey M. Cosgrove, David M. O’Malley et al. · 2023 · Gynecologic Oncology
32. Vitamin D and prebiotics for intestinal health in cystic fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 x 2 trial of administration of prebiotics and cholecalciferol (vitamin D3) (Pre-D trial) in adults with cystic fibrosis
    Alisa K. Sivapiromrat, Pichatorn Suppakitjanusant, Yanling Wang, Chengcheng Hu, José Binongo, William R. Hunt, Samuel Weinstein, Ishaan Jathal, Jessica A. Alvarez, Benoît Chassaing et al. · 2024 · Contemporary Clinical Trials Communications
33. Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort
    Salem Alshemmari, Ahmad J Al-Sarraf, Andy J. Kaempf, Alexey V. Danilov · 2024 · BMC Cancer
34. Multidisciplinary Consensus for Rationalizing the Use of Acid Suppressants in Children and Adults: CONFOR
    Vijay Kher, Manav Wadhawan, Arun Wadhwa, Sadanand Shetty, Shrish Bhatnagar, Ram Y Prabhoo, Uday Pai, Bhanu Vikraman Pillai, Chris D'souza, Manish Bhatnagar et al. · 2024 · Euroasian Journal of Hepato-Gastroenterology
35. Proton-Pump Inhibitors and Serum Concentrations of Uremic Toxins in Patients with Chronic Kidney Disease
    Carolla El Chamieh, Islam Amine Larabi, Solène M. Laville, Christian Jacquelinet, Christian Combe, Denis P. Fouque, Maurice Laville, Luc Frimat, Roberto Pecoits‐Filho, Céline Lange et al. · 2023 · Toxins
36. Gastrointestinal Dysfunction in Genetically Defined Neurodevelopmental Disorders
    Elizabeth A. Davidson, Calliope Holingue, Andrés Jiménez-Gómez, Julia E. Dallman, Baharak Moshiree · 2023 · Seminars in Neurology
37. Understanding the health risks and emerging concerns associated with the use of long-term proton pump inhibitors
    Nathan Michael Morris, Meghali Nighot · 2023 · Bulletin of the National Research Centre/Bulletin of the National Research Center
38. Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial
    Piotr Dziechciarz, Katarzyna Krenke, Hania Szajewska, Andrea Horvath · 2020 · Pediatric Gastroenterology Hepatology & Nutrition
39. Xenobiotics mediated modulation of gut microbiota and its role in lifestyle diseases: a critical appraisal on exposomics
    Arush Behl, Krishna Kant Sharma · 2025 · Letters in Applied Microbiology
40. Targeting Irritable Bowel Syndrome Through Diet and Mechanism-Based Therapies: A Pathophysiological Approach
    Ioanna Aggeletopoulou, Katerina Karaivazoglou, Maria Kalafateli, Christos K Triantos · 2025 · Nutrients
41. Proton pump inhibitor increases intestinal epithelial paracellular permeability via the p38-MAPK/NF-κB signaling pathway
    Meng Zhang, Wei Liu, Yunhui Liu, Qiuyu Cheng, Xiaolei Zhang, Na Qian, Junying Qi, Tao Chen, Yan Yu · 2025 · Molecular Biology Reports
42. Impact of different gastric acid suppressants on chronic unpredictable mild stress-induced cognitive impairment in rats: A possible involvement of gut dysbiosis
    Reem M Eladawy, Lamiaa A. Ahmed, Maha Badr Salem, Olfat Ali Hammam, Ahmed F. Mohamed, Hesham A. Salem, Rehab M. El‐Sayed · 2024 · Toxicology and Applied Pharmacology
43. Metagenomic Analysis of Gut Microbiota for Abdominal Aortic Aneurysm
    Eisaku Ito, Takao Ohki, Naoki Toya, Takuo Emoto, Tomoya Yamashita, Tomomi Sugiyama, Takuji Yamada, Hiroshi Mori, Atsushi Toyoda, Ken‐ichi Hirata · 2025 · Annals of Vascular Diseases
44. Drug-Related Enteropathy
    Octavio Gomez-Escudero · 2022 · IntechOpen eBooks
45. Re-thinking the possible interaction between proton pump inhibitors and capecitabine
    Soo Hee Jeong, Lara Molloy, Edmond Ang, Nuala Ann Helsby · 2022 · Cancer Chemotherapy and Pharmacology
46. Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment
    Baohui Hong, Rong Chen, Caiyun Zheng, Maobai Liu, Jing Yang · 2024 · Cancer Medicine
47. Prescribing Responsibly: Navigating the Tides of Deprescribing in Proton Pump Inhibitor Stewardship
    Anna Peyton-Navarrete, Minh Hien Chau Nguyen, Alireza FakhriRavari · 2025 · Pharmacoepidemiology
48. A comparison of different symptomatic reflux esophagitis treatments: A real-world study
    Francesco Di Mario, Pellegrino Crafa, Lorella Franzoni, Tursi Antonio, Giovanni Brandimarte, Michele Russo, Kryssia Isabel Rodriguez-Castro, Marilisa Franceschi, Nicola de Bortoli, Edoardo Vincenzo Savarino · 2023 · Advances in Clinical and Experimental Medicine
49. Effect of Vonoprazan, potassium-competitive acid blocker, on Atezolizumab plus Bevacizumab efficacy in patients with hepatocellular carcinoma: a multicenter retrospective study
    Masaya Takahashi, Katsuyuki Takahashi, Sawako Uchida‐Kobayashi, Yuzuka Sasa, Hirotake Yamase, Daichiro Fujiwara, Tomohiro Yoshikawa, Yuika Komatsu, Masahito Shibano, Hiroki Arie et al. · 2025 · International Journal of Clinical Oncology
50. Exacerbation Risk by Chronic Proton Pump Inhibitor Use in Obstructive Lung Diseases
    Valerie Dehondt, Frauke Van Vaerenbergh, Katia M.C. Verhamme, Lies Lahousse · 2026 · CHEST Journal
51. The biogeography of the mucosa-associated microbiome in health and disease
    Peter R. Sternes, Ayesha Shah, Camila Ayala Pintos, Thomas Fairlie, Natasha A. Koloski, Seungha Kang, Kaylyn D. Tousignant, Simon Jon McIlroy, Mark Morrison, Gene W. Tyson et al. · 2024 · Frontiers in Microbiology
52. Impact of concomitant medications on the oncologic efficacy of systemic therapy in patients with advanced or metastatic urothelial carcinoma: a systematic review and meta-analysis
    Ichiro Tsuboi, Akihiro Matsukawa, Mehdi Kardoust Parizi, Marcin Miszczyk, Tamás Fazekas, R. J. Schulz, Ekaterina Laukhtina, Tatsushi Kawada, Satoshi Katayama, Takehiro Iwata et al. · 2025 · BMC Urology
53. The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis
    Ichiro Tsuboi, Akihiro Matsukawa, Mehdi Kardoust Parizi, Marcin Miszczyk, Tamás Fazekas, R. J. Schulz, Stefano Mancon, Giulio Litterio, Ekaterina Laukhtina, Tatsushi Kawada et al. · 2024 · Clinical Genitourinary Cancer
54. Gastrointestinal symptoms in COVID-19 could be associated with severe lung involvement and increased readmission rates
    Hüseyin Sancar Bozkurt, Ömer Bilen · 2021 · European Journal of Inflammation
55. Nutrition in Viral Hepatitis
    Dibya Lochan Praharaj, Anil Chandra Anand · 2023 · Current Hepatology Reports
56. Associated Factors to Efficacy and Tolerance of Immunotherapy in Older Patients with Cancer Aged 70 Years and Over: Impact of Coprescriptions
    Marie Perret, Aurélie Bertaut, Julie Niogret, Sophie Marilier, P. Jouanny, Patrick Manckoundia, Leïla Bengrine-Lefèvre, Valérie Quipourt, Jérémy Barben · 2023 · Drugs & Aging
57. Acupoint catgut embedding advantage in treating gastro-oesophageal reflux disease (ACE-GERD): study protocol for a randomised controlled trial
    Shuting Wen, Xiying Zhao, Xiaofeng Lin, Zhaoli Fu, Shumin Qin, Qimou Pan, Fengbin Liu, Wenfang He, Tianwen Liu · 2024 · BMJ Open
58. Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors
    Igor Veniaminovich Maev, Д. Н. Андреев, R. I. Shaburov, Andrey Vladimirovich Zaborovsky, Алексей Константинович Фоменко, Filipp S. Sokolov, Sergei V. Tsaregorodtsev, Mikhail K. Devkota, Diana T. Dicheva, Sergei V. Cheremushkin et al. · 2025 · Terapevticheskii arkhiv
59. Immunological Drug–Drug Interactions in Immune Checkpoint Inhibitor Therapy: Mechanisms, Clinical Evidence, and Artificial Intelligence
    Chin Hang Yiu, Kevin Winardi, Christine Y. Lu · 2026 · Current Oncology Reports
60. The Impact of Concomitant Proton Pump Inhibitors Therapy on Clinical Outcome of Cancer Patients Treated With Immune Checkpoint Inhibitors
    Xing Cao, Yafei Wang, Wei Huang, Panyun Li, Chongjie Guo, Yuhui Li · 2023 · American Journal of Clinical Oncology
61. Long-Term Usage of Proton Pump Inhibitors Associated with Prognosis in Patients with Colorectal Cancer
    Chin-Chia Wu, Chuan‐Yin Fang, Ben‐Hui Yu, Chun‐Ming Chang, Ta-Wen Hsu, Chung-Lin Hung, Shih‐Kai Hung, Wen‐Yen Chiou, Jui‐Hsiu Tsai · 2023 · Cancers
62. Intestinal dysbiosis and increased intestinal permeability as a potential risk factor for the development and progression of rheumatoid arthritis
    Karolina Zofia Wąż, Eugeniusz Józef Kucharz, Magdalena Kopeć-Mędrek, Robert Pieczyrak, Przemysław Jacek Kotyla · 2022 · Rheumatology Forum
63. Integrative Geriatric Oncology: A Review of Current Practices
    H. A. Fine, Amrita Bonthu, Mikhail Kogan · 2024 · Current Oncology Reports
64. Gastroprotection in Heart Failure and Outcomes: A Systematic Review of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists
    Mustafa Eray Kılıç, Mehmet Birhan Yılmaz · 2024 · Cardiovascular Drugs and Therapy
65. ВЗАИМОДЕЙСТВИЕ ЭССЕНЦИАЛЬНЫХ ЭЛЕМЕНТОВ И КИШЕЧНОЙ МИКРОБИОТЫ: ОБЗОР ЛИТЕРАТУРЫ
    ФГАОУ ВО «Московский государственный университет имени М.В. Ломоносова», В.В. Грабеклис, О. В. Делюкина, ООО «ОЛЛМЕД ПЛЮС», Sergey A. Savko, ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет) · 2023 · Trace Elements in Medicine (Moscow)
66. A pilot study to investigate the fecal dissemination of SARS-CoV-2 virus genome in COVID-19 patients in Odisha, India
    Shantibhusan Senapati, Jaya Singh Kshatri, Punit Prasad, Jyotirmayee Turuk, Sanghamitra Pati, Ajay Kumar Parida · 2020 · medRxiv
67. Expansion of a versatile pathogen: Clostridioides difficile
    Tereena Lucas, Brent Brown · 2024 · Hygiene and Environmental Health Advances
68. Repositioning Proton Pump Inhibitors: Expanding Applications from Acid Suppression to Cancer Therapeutics
    Erica Alves, Bannimath Gurupadayya, Prabitha Prabhakaran · 2025 · Clinical Cancer Drugs
69. Microbiological Characteristics of Intestinal Biocenosis of Ambulator Patients Having Behavioral Risk Factors for Chronic Non-Communicable Diseases
    I. А. Кrylova, Vitalii I. Kupaev, A. V. Ljamin · 2021 · The Russian Archives of Internal Medicine
70. Gastric pyrosis and hyperacidity: an outstanding task in clinical practice. The positioning of a new multicomponent medical device containing sodium alginate, tamarind seed extract, and carbonates
    Salvo Emanuele Aragona, Giorgio Ciprandi · 2023 · Gazzetta Medica Italiana Archivio per le Scienze Mediche
71. Gastrointestinal health and therapeutic carbohydrate restriction
    Natasha Campbell-McBride, Sarah M. Rice, Tamzyn Murphy · 2023 · Elsevier eBooks
72. Pantoprazole promotes sustained intestinal carriage of multidrug-resistant Escherichia coli in amoxicillin-treated mice
    Camille Moaligou, Michel Dion, Murad Mohammad Ishnaiwer, Éric Dailly, Éric Batard, François Javaudin · 2023 · Journal of Applied Microbiology
73. Effects of 1‐kestose on microbiome changes caused by vonoprazan: a randomized, double‐blind, placebo‐controlled pilot study
    Satoshi Furune, Takahiro Suzuki, Takashi Honda, Kenta Yamamoto, Kazuhiro Furukawa, Masanao Nakamura, Masatoshi Ishigami, Fumie Kinoshita, Yoshihiro Kadota, Takumi Tochio et al. · 2023 · Journal of Gastroenterology and Hepatology
74. Impact of proton pump inhibitors on periodontal health – A systematic review
    Hajer A. Aldulaijan · 2024 · The Saudi Dental Journal
75. Proton Pump Inhibitors Are Associated with Increased Risk of Psoriasis: A Nationwide Nested Case-Control Study
    Cheng‐Yuan Li, Ying‐Xiu Dai, Yun-Ting Chang, Ya‐Mei Bai, Shih‐Jen Tsai, Tzeng‐Ji Chen, Mu‐Hong Chen · 2021 · Dermatology
76. The Complex Interaction between Proton Pump Inhibitors and Cancer Treatment
    Hao Chen, Masaaki Kondo, Nobuyuki Horita, Kenichi P. Takahashi, Takeshi Kaneko · 2023 · Cancers
77. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab
    Takanori Sekito, Kensuke Bekku, Satoshi Katayama, Tomofumi Watanabe, Ichiro Tsuboi, Kasumi Yoshinaga, Yuki Maruyama, Tomoaki Yamanoi, Tatsushi Kawada, Yusuke Tominaga et al. · 2024 · Clinical Genitourinary Cancer
78. Contribution of the Microbiota to Healthy Aging
    Sofia D. Forssten, Arthur C. Ouwehand · 2021 · Elsevier eBooks
79. Esophagogastric microbiome—Internal and external influences effecting variance
    Byung Soo Yoo, Alsiddig Elmahdi, Ana Vilela, Steve M. D’Souza, Kevin V. Houston, David A. Johnson · 2023 · Elsevier eBooks
80. Maintenance proton pump inhibitor use and risk of colorectal cancer: a Swedish retrospective cohort study
    Qing Liu, Xinchen Wang, Lars Engstrand, Omid Sadr‐Azodi, Katja Fall, Nele Brusselaers · 2024 · BMJ Open
81. Proton Pump Inhibitors Worsen Colorectal Cancer Outcomes in Patients Treated with Bevacizumab
    Chin-Chia Wu, Chuan‐Yin Fang, Wen‐Yen Chiou, Pei-Tsen Chen, Ta-Wen Hsu, Shih‐Kai Hung, Yu‐Tso Liao, Chuan-Sheng Hung, Jui‐Hsiu Tsai · 2024 · Cancers
82. Genotoxic effects of NDMA-contaminated ranitidine on Allium cepa cells and unveiling carcinogenic mechanisms via DFT and molecular dynamics simulation study
    Mst. Kusum Kaly, Md. Ekhtiar Rahman, Md. Sohel Rana, Uzzal Kumar Acharjee, Khondokar Nasirujjaman · 2024 · Scientific Reports
83. Effect of Omeprazole on Esophageal Microbiota in Dogs Detected Using a Minimally Invasive Sampling Method
    Aditi Handa, Giovana Simão Slanzon, Yoko M. Ambrosini, Jillian M. Haines · 2025 · Journal of Veterinary Internal Medicine
84. Roles of chemical species transport and transformation in the biophysics of human pathophysiology
    Kazeem Bode Olanrewaju, Ashlee N. Ford Versypt · 2025 · npj Biological Physics and Mechanics.
85. Proton pump inhibitor exposure modulates functional and transcriptional responses in Lactobacillus acidophilus: a comprehensive computational and experimental insights
    Romen Singh Naorem, Kalpajit Dutta, Sudipta Sankar Bora, Anju Barhai Teli · 2026 · Frontiers in Cellular and Infection Microbiology
86. Periodontitis and Inflammatory Bowel Diseases: Mechanistic Evidence
    Ana Paula Vieira Colombo, Adriana M. de Oliveira, Nobuhiko Kamada, Sho Kitamoto · 2026 · Journal of Periodontal Research
87. A review of current evidence and perspectives on the mechanisms and clinical significance of hypoxia-induced remodeling of the gastric microbiota-metabolism axis
    Yu Zhang, Zhe Yuan · 2026 · Frontiers in Microbiology
88. Dependence of the state of the large intestine parietal microflora on the activity of Helicobacter pylori associated chronic gastritis
    H.B. Isayev, M.R. Ibrahimov, T. H. Salimov · 2021 · Ural Medical Journal
89. Gastroprotective therapy in patients with atrial fibrillation receiving anticoagulant therapy: A review
    Ol'ga Dmitrievna Ostroumova, А. И. Кочетков, Батюкина Светлана Владимировна, Sergei V. Cheremushkin · 2023 · Consilium Medicum
90. Association between proton pump inhibitor use and the risk of hepatobiliary cancers: A meta‐analysis
    Tai-Yung Yi, Tzu‐Rong Peng, Ta‐Wei Wu, An‐Jan Wu · 2024 · Advances in digestive medicine
91. A Meta-Analysis of Proton Pump Inhibitor Exposure and the Risk of Adverse Outcomes in Patients with Inflammatory Bowel Disease
    Qiufeng Zhang, Dandi Lou, Yueming Zhang, Anyi Xu, Yingying Fang, Xiaoshuai Zhou · 2024 · Digestive Diseases
92. Impact of concomitant use of proton pump inhibitors or cardiovascular medication on survival outcomes of patients with metastatic renal cell carcinoma treated with nivolumab
    Ondřej Fiala, Petr Hošek, Michaela Tkadlecová, Bohuslav Melichar, Anežka Zemánková, Jindřich Kopecký, Michal Vočka, Martin Matějů, Radka Lohynská, Dominika Šiková et al. · 2025 · Clinical & Experimental Metastasis
93. Association between the chronic use of gastric acid suppressants and high‐risk colorectal polyps
    Yasutoshi Shiratori, Takashi Ikeya, Naoki Ishii, Kazuki Yamamoto, Tetsuro Honda, Kenkei Hasatani, Naohiro Yoshida, Tsutomu Nishida, Tetsuya Sumiyoshi, Shu Kiyotoki et al. · 2021 · JGH Open
94. Supporting Gut Health by Homeostasis and Intrinsic Mechanisms
    Jennifer Gantzer · 2021 · Acta Scientific Neurology
95. Concomitant of Proton Pump Inhibitors is Associated with Poor Clinical Outcomes in Patients Treated with Immune Checkpoint Inhibitors ：An Up-to-date Systematic Review and Meta-analysis
    Haiyan Mao, Jiandong Tong, Xuebing Yan, Chaoxing Liu, Mengxue Yang, Huaijuan Guo · 2021 · Research Square
96. PPIs and anti-TNF in patients with IBD: a forbidden combination?
    Judith Wellens, João Sabino, Séverine Vermeire · 2021 · Gut
97. Proton Pump Inhibitors, Associated Complications, and Alternative Therapies: A Shifting Risk Benefit Ratio
    Alexander Friedman, Anna J. Elseth, Joel R. Brockmeyer · 2021 · The American Surgeon
98. Impact of Helicobacter Pylori Eradication Therapy on Gastric Microbiome
    Li-Qi Mao, Yanlin Zhou, Shuangshuang Wang, Lin Chen, Yue Hu, Lei-Min Yu, Jingming Xu, Bin Lü · 2021 · Research Square
99. Chirurgische Behandlung der Refluxkrankheit
    Andreas Thalheimer · 2021 · Im OP
100. Breaking down the barriers : The effects of aging, gut microbiota and bile acids on intestinal health
     Benthe van der Lugt · 2021